NXPL

Business Context and Reporting Period

Company: Nextplat Corp (NXPL)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three months ended March 31, 2026

Business Overview: Nextplat operates two primary segments: e-Commerce Operations (satellite communication equipment and services) and Healthcare Operations (pharmacy services, 340B contract pharmacy, and healthcare data analytics). The company is a smaller reporting company listed on the Nasdaq Capital Market.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 29% ($4.07 million) year-over-year. This was driven by a 50% drop in Healthcare prescription revenue ($4.71 million decrease) due to lower reimbursement rates and reduced volume. This was partially offset by a 6% increase in e-Commerce revenue ($0.19 million increase) driven by higher airtime sales.
• Margin Expansion: Despite lower revenue, gross margin improved significantly from 20.6% to 34.6%. Healthcare segment margins rose to 39% from 20%, attributed to higher-margin contract pharmacy services and the implementation of the Medicare Maximum Fair Price program.
• Expense Reduction: Operating expenses decreased by 9% ($0.43 million), primarily due to a reduction in salaries and wages ($0.30 million) resulting from headcount reductions and lower executive compensation, and a 62% drop in depreciation and amortization.
• Cash Flow: Net cash used in operating activities increased to $2.58 million from $2.06 million, largely due to timing differences in receivable collections and inventory purchases.

Outlook, Risks, and Contingencies

• Liquidity and Going Concern: Management previously raised substantial doubt about the company's ability to continue as a going concern due to recurring losses. However, management now believes this doubt is mitigated by current liquidity ($11 million cash), cost reduction measures, and access to capital via a new At-The-Market (ATM) offering program.
• Capital Raising: On May 13, 2026, the company entered into an ATM agreement to sell up to approximately $3.74 million of common stock. No sales have occurred as of the filing date.
• Nasdaq Compliance: The company previously failed to meet the $1.00 minimum bid price requirement. It effected a 1-for-10 reverse stock split on April 13, 2026, and regained compliance with Nasdaq on April 27, 2026.
• Legal Contingency: A putative class action lawsuit regarding the 2024 merger with RXMD Therapeutics remains pending. The company has accrued $1.75 million for this matter, representing its insurance retention. The ultimate loss could differ materially.
• Internal Controls: The company disclosed material weaknesses in internal controls related to accounting estimates for PBM performance bonuses and the valuation of PIPE warrant modifications. These remain unremediated as of March 31, 2026.

Investor Verification Checklist

• Revenue Sustainability: Verify the durability of the improved gross margins in the Healthcare segment given the significant drop in prescription volume and reliance on the new Medicare Maximum Fair Price program.
• Cash Burn Rate: Monitor the $2.58 million quarterly operating cash burn against the $11 million cash balance to assess runway without immediate equity dilution.
• Legal Exposure: Track the status of the Weisberg v. Nextplat litigation to determine if the $1.75 million accrual is sufficient or if additional reserves are needed.
• ATM Utilization: Watch for filings indicating sales under the new ATM program, which could dilute existing shareholders but provide necessary working capital.
• Internal Control Remediation: Review future filings for progress on remediating the material weaknesses in financial reporting controls.